Source: PR Newswire

Press Release: Namocell : NAMOCELL HIGHLIGHTED IN NATURE PUBLICATION FOR EFFICIENT SINGLE CELL CLONING OF HUMAN PLURIPOTENT STEM CELLS

MINNEAPOLIS, Nov. 17, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a single-cell cloning workflow study using the Namocell Single Cell Dispenser in Nature Protocols: Efficient and safe single-cell cloning of human pluripotent stem cells...

Read full article »

Namocell's Competitors | Namocell's News | Namocell's Financials

Followers on Owler

114

Est. Annual Revenue

$5.0-25M

Est. Employees

25-100

Founder & CEO

Junyu Lin

CEO Approval Rating

83/100

Namocell is a California-based biotechnology company that provides solutions such as single cell genomics, cell line development, antibody discovery and synthetic biology.